China Proton Therapy Market is expected to grow with a CAGR of 25 % in future. China Proton Therapy Market is expected to triple by the end of 2021 from its current market in 2016. Currently China has only two proton therapy facilities. However the scenario is going to make a drastic change in the next few years when China will have at least 6 new Proton Therapy Centers.
China Proton Therapy Market & Forecast, Patients Treated at Proton Therapy Facility, Reimbursement Policy is a report published by Renub Research. In this report we have studied the market in two parts a) Actual Market and b) Untapped Market. The report also talks about list of all Operational and about to be opened Proton Therapy Facility. Proton Therapy revenues from 3 companies (IBA, Varian Medical Systems, Elekta) has also been studied in the report.
a) Actual Market is the current market which is already present
b) Untapped Market is the market which can be achieved; but it has yet not been achieved due to demand and supply gap. At present only a few proton therapy centers are available that can treat a limited number of patients each year.
China Proton Therapy Market has been analyzed from four view points
- China Proton Therapy Actual Market & Forecast (2009 – 2021) - China Proton Therapy Untapped Market & Forecast (2009 – 2021) - China Proton Therapy Treated Patient Numbers & Forecast (2009 – 2021) - China Proton Therapy Untapped Patient Numbers & Forecast (2009 – 2021)
Key Companies Covered
1. IBA (Overview, Sales Analysis) 2. Varian Medical Systems (Overview, Sales Analysis) 3. Elekta (Overview, Sales Analysis)
Key Questions Answered in the Report?
- What is the Proton Therapy Market in China & its growth potential in Future? - What is the untapped Proton Therapy Market in China and its Future growth? - How many Proton Therapy Facilities are operating in China? - How many Proton Therapy Facilities are going to open in near Future? - What is the number of people being treated in these Proton Therapy Facilities yearly? - Is Proton Therapy Treatment being covered in the Reimbursement policy of China? - What are the sales of Proton Therapy Companies Globally (IBA, Varian, Elekta)?
Our reports have been used by over 10K customers, including:
172 pages •
By Global Industry Analysts
• Apr 2021
Abstract:
- Global Myeloproliferative Disorders Drugs Market to Reach $9.9 Billion by 2027
- Amid the COVID-19 crisis, the global market for Myeloproliferative Disorders Drugs estimated at US$7.8 Billion in the year 2020, is projected to reach a revised size of US$9.9 Billion by 2027, growing at aCAGR of 3.4% over...
High-Grade Glioma (Oncology) - Drugs in Development, 2021 Summary High-Grade Glioma (Oncology) - Drugs in Development, 2021 provides an overview of the High-Grade Glioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for High-Grade Glioma,...
Soft Tissue Sarcoma (Oncology) - Drugs in Development, 2021 Summary Soft Tissue Sarcoma (Oncology) - Drugs in Development, 2021 provides an overview of the Soft Tissue Sarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Soft Tissue...
Malignant Fibrous Histiocytoma (Oncology) - Drugs in Development, 2021 Summary Malignant Fibrous Histiocytoma (Oncology) - Drugs in Development, 2021 provides an overview of the Malignant Fibrous Histiocytoma pipeline landscape. The report provides comprehensive information on the therapeutics...
Myeloproliferative Disorders (Oncology) - Drugs in Development, 2021 Summary Myeloproliferative Disorders (Oncology) - Drugs in Development, 2021 provides an overview of the Myeloproliferative Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under...
Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Drugs in Development, 2021 Summary Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium...
Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Drugs in Development, 2021 Summary Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Proto-oncogene serine/threonine-protein kinase Pim-1 is an enzyme encoded by the PIM1 gene. It promotes...
Fallopian Tube Cancer Market Report Overview Fallopian Tube Cancer market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Fallopian Tube Cancer market types and applications. It is a focused study on Fallopian Tube Cancer market space including...